SPI Infoamtion

このレポートは章ごとの個別販売も行っておりますのでお問い合わせ下さい。
※全てPDFでの販売となります。

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED BCC REPORTS
BCC ONLINE SERVICES
DISCLAIMER

Chapter-2: SUMMARY

SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2008-2014 ($ MILLIONS)
FORECAST SUMMARY

Chapter-3: OVERVIEW

DEFINITION AND MARKET STRUCTURE
WHAT IS ALZHEIMER'S DISEASE?
TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2000--2050 (MILLIONS)
FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2000--2050 (MILLIONS)
Role of the Cholinergic System
Role of Beta-Amyloid Protein
Behavioral Manifestations of AD
INCIDENCE AND PREVALENCE
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2009--2050 (MILLIONS)
TABLE 3 PERCENT POPULATION OVER 65, BY REGION (%)
TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS)
FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE, BY AGE GROUP, 2004-2050 (MILLIONS)
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET (%)
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%)
STAGES OF ALZHEIMER'S DISEASE
DIAGNOSIS
TABLE 7 DIAGNOSTIC TESTS
How Accurate are the Screening Tests?
KEY EVENTS
PATENT EXPIRATIONS
NEW PRODUCT LAUNCHES
PRICING
KEY MARKETS
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, THROUGH 2014 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2008-2014 ($ MILLIONS)
MARKET SIZE AND KEY PLAYERS
THERAPEUTICS
TABLE 9 EXISTING TREATMENTS: ALZHEIMER'S DISEASE
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S DISEASE, BY TYPE, 2002--2009 ($ MILLIONS)
TABLE 11 GLOBALMARKET FOR ALZHEIMER'S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN), 2009 ESTIMATED ($ MILLIONS)
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE, 2008
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%)
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE STATE (%)
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%)
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2014 ($ MILLIONS)
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2007-2014 ($ MILLIONS)
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2014 ($ MILLIONS)
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2008 (%)
Key Players
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%)
TABLE 20 MARKETED TREATMENTS: ALZHEIMER'S DISEASE
Drivers
Issues and Challenges
IMAGING AND DIAGNOSTICS
Current Use in Alzheimer's Disease
Diagnostic Testing Segments
Imaging
TABLE 21 IMAGING MARKET, 2008 ($ MILLIONS)
FIGURE 7 IMAGING MARKET, 2008 ($ MILLIONS)
Standardization Needed
Diagnostics
Novel Imaging Agents
Opportunities for Biomarkers in AD
TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2014 ($ MILLIONS)
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2008-2014 ($ MILLIONS)
TABLE 24 U.S. CLINICAL TRIAL MARKET FOR BIOMARKERS BY PHASE―NUMBER OF TRIALS, PATIENTS, BIOMARKER PATIENTS, COST PER TEST, MARKET SIZE, 2008
TABLE 25 CLINICAL TRIAL MARKET FOR BIOMARKERS BY GEOGRAPHICAL REGION, 2008 ($ MILLIONS)
Testing Hypotheses
Diagnostic Tests
Key Players
Agilent Technologies
Bioscan
Capintec Inc.
Digirad Corporation
Gamma Medica-Ideas
GE Healthcare
Hitachi Medical Systems America Inc.
Nymox
OptoSonics Inc.
Philips Healthcare
Positron Corp.
Siemens Healthcare
Spectrum Dynamics Ltd.
Toshiba Medical Systems
UltraSPECT Ltd.
VisEn Medical Inc.
Zecotek Imaging Systems
Drivers
Issues and Challenges
SWOT ANALYSIS
TABLE 26 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND PLAYERS

Chapter-4: TECHNOLOGIES AND APPLICATIONS

COMMON MECHANISMS OF ACTION
CHOLINESTERASE INHIBITORS
TABLE 27 CHOLINESTERASE INHIBITORS
TABLE 28 PRODUCT SIDE EFFECT COMPARISON (%)
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%)
TABLE 29 VACCINES
TABLE 30 ANTI-OXIDANTS
NMDA ANTAGONISTS
TABLE 31 NMDA ANTAGONISTS
NICOTINICS
TABLE 32 NICOTINIC ACETYLCHOLINE ANTAGONISTS
CALCINEURINS
TABLE 33 CALCINEURINS
GABA MODULATORS
TABLE 34 ANTI-EPILEPTIC/GABA MODULATORS
HORMONES
TABLE 35 HORMONES
OTHER THERAPEUTIC MECHANISMS
TABLE 36 OTC TREATMENTS/NATURAL PRODUCTS
IMAGING AND DIAGNOSTICS―MODALITIES AND APPLICATIONS
NUCLEAR MEDICINE
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Gamma Cameras
CT (COMPUTED TOMOGRAPHY)
DEXA
MRI (MAGNETIC RESONANCE IMAGING)
ULTRASOUND
X-RAY
FUSION IMAGING
PET/CT
SPECT/CT
SPECT-CT in Cardiology
SPECT-CT in General Nuclear Medicine
SPECT-CT in Neurology
DIAGNOSTIC IMAGING IN ALZHEIMER'S
DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS
SYMPTOMATIC RELIEF―LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS
OTHER DRUGS TARGETING SYMPTOMATIC RELIEF
DRUG RE-PURPOSING
GENERICS

Chapter-5: WORLDWIDE INDUSTRY STRUCTURE

GROWTH DRIVERS
AGING POPULATION
OFF-LABEL USE
UNDERSTANDING OF MECHANISMS
Transcranial Magnetic Stimulation
Genetic Modifications
GROWTH OBSTACLES
UNDERSTANDING OF MECHANISMS
TABLE 37 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%)
CO-MORBID DISEASE STATES
KEY COMPETITIVE FACTORS
PRODUCT LAUNCH
LIFE CYCLE MANAGEMENT
PAYORS
INTERNATIONAL ASPECTS
TABLE 38 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2006 ($ MILLIONS)

Chapter-6: LEGISLATION AND REGULATORY ENVIRONMENT

VALIDATED TARGETS
LACK OF BIOMARKERS
TRANSLATIONAL MEDICINE
REIMBURSEMENT

Chapter-7: RELATED DEALS AND PARTNERSHIPS

APPROACH
DIAGNOSTICS DEALS
OVERALL ACTIVITY
TABLE 39 RELATED DEALS AND PARTNERSHIPS, 2004--2009

Chapter-8: PIPELINE

PIPELINE
TABLE 40 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE

Chapter-9: TRENDS AND CHALLENGES

AWARENESS OF ALZHEIMER'S
DISEASE PATHWAYS BEING ELUCIDATED
MANY PROGRAMS IN DEVELOPMENT
TABLE 41 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD AREA
TABLE 42 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES

Chapter-10: OUTLOOK

A VARIETY OF APPROACHES IN RESEARCH
MANY PROGRAMS IN DEVELOPMENT

Chapter-11: PATENT ANALYSIS

TABLE 43 KEY PATENT EXPIRY―ALZHEIMER'S THERAPEUTICS, BY CATEGORY
TABLE 44 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S THERAPEUTICS AND TECHNOLOGIES
TABLE 45 PATENT APPLICATIONS (U.S.)
TABLE 46 ISSUED PATENTS (U.S.)

Chapter-12: COMPANY PROFILES

ABLYNX
ACCERA, INC.
ACUMEN PHARMACEUTICALS
AFFIRIS AG
AFFITECH AS
ALLON THERAPEUTICS (FKA NEURODISCOVERY)
ALZHYME PTY
ASTELLAS
ASTRAZENECA
ATHENA DIAGNOSTICS (THERMO FISHER)
AVERA PHARMACEUTICALS
BAXTER HEALTHCARE
BAYER SCHERING PHARMA
BELLUS HEALTH
BIOFUTURA
BIOMERIEUX
BIOVAIL
BOEHRINGER INGELHEIM
BRACCO
BRAINCELLS, INC.
BRISTOL MYERS SQUIBB
CELLZOME
CEREGENE
COGNITION PHARMACEUTICALS LLC
COGNITION THERAPEUTICS
COLUCID PHARMACEUTICALS
COMENTIS
CORTEX PHARMACEUTICALS
C2N DIAGNOSTICS
CYTOS BIOTECHNOLOGY
DAIICHI SANKYO
DEBIOPHARM
DURECT
EISAI
ELAN
ELI LILLY
ENVIVO PHARMACEUTICALS
ESTEVE
EVOTEC
EXONHIT THERAPEUTICS
FOREST LABORATORIES
GALANTOS PHARMA
GALENEA
GE HEALTHCARE
GLAXOSMITH KLINE
HELICON THERAPEUTICS
INTELLECT NEUROSCIENCES
INTRA-CELLULAR THERAPIES
INVERNESS MEDICAL INNOVATIONS
IPSEN
JOHNSON & JOHNSON
KEYNEUROTEK
LEXICON PHARMACEUTICALS
LINK MEDICINE
LUNDBECK
MEDIVATION
MEMORY PHARMACEUTICALS
MERCK
MERCKSERONO
MERZ PHARMA
MITHRIDION
MITSUBISHI TANABE
MORPHOSYS
MP BIOMEDICALS
NEUREN PHARMACEUTICALS
NEUROPTIX
NEUROSEARCH
NEURO-HITECH
NEWRON PHARMACEUTICALS
NOSCIRA SA
NOVARTIS
NYMOX
OLIGOMERIX
ORTHO-MCNEIL NEUROLOGICS
PFIZER
POWER3 MEDICAL PRODUCTS
PRANA BIOTECHNOLOGY
PROTEOTECH INC.
PSYCHOGENICS
ROCHE
SAMARITAN PHARMACEUTICALS
SANOFI-AVENTIS
SATORI PHARMACEUTICALS
SATORIS
SCIELE PHARMA
SIEMENS MEDICAL SOLUTIONS
SOLVAY
SUVEN LIFE SCIENCE
TAKEDA
TARGACEPT
TAURX THERAPEUTICS
TAUTATIS
TEIKOKU
TEVA PHARMACEUTICALS
TRANSTECH PHARMA
VOYAGER PHARMACEUTICAL / DURAMED
WATSON PHARMACEUTICALS
WYETH/PFIZER